Skip to main content
Download PDF

Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis

World Journal of Surgical Oncology volume 21, Article number: 349 (2023) Cite this article

Abstract

Background

The effectiveness and safety of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors is controversial. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors as neoadjuvant therapy for malignant solid tumors.

Methods

This study has been registered with the number CRD42023407275 on PROSPERO. Systematic searches were conducted in PubMed, Embase, Web of Science and Cochrane Library databases until March 17, 2023. In addition, manual searches were performed. The inclusion criteria encompassed randomized controlled trials (RCTs) that assessed the utilization of neoadjuvant PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors PD-1/PD-L1 inhibitors for patients with solid malignancies. The Cochrane Collaboration's tool for assessing risk of bias in randomized trials (ROB1) were used. Risk ratios (RRs), hazared ratios (HRs) and their respective 95% confidence intervals were calculated using Stata17.0 MP and Review Manager 5.4 software.

Results

A total of 2780 records were identified, and ultimately 10 studies involving 273 patients were included. The meta-analysis showed that the addition of CTLA-4 inhibitors to PD-1/PD-L1 inhibitors did not demonstrate a significant effect on overall response rate, main pathological response, pathological complete response, surgical resection, radical resection, overall survival, progression-free survival, recurrence-free survival, grade 3–4 adverse events, all-cause mortality, and completed treatment (P > 0.05). However, further subgroup analysis indicated that the combination of PD-1 with CTLA-4 inhibitors significantly increased the occurrence of grade 3–4 adverse events in patients (P < 0.05).

Conclusions

As neoadjuvant therapy for malignant solid tumors, the addition of CTLA-4 inhibitors to PD-1/PD-L1 inhibitors does not appear to enhance efficacy.Moreover, there is a potential increase in the risk of grade 3–4 adverse events associated with this combination. However, it is important to note that the studies included in this analysis suffer from limitations such as small samples and single-center designs, which are inherent constrains with the available published literature. Further research involving large-sample and multicenter RCTs are warranted to obtain more reliable results.

Introduction

In 70 countries, cancer is the second leading cause of death following cardiovascular diseases. Remarkably, in 57 countries cancer has even surpassed cardiovascular disease to become the top spot in mortality among humans [1]. Nearly 10 million people worldwide died of cancer in 2020 [2]. Therefore, conquering cancer assumes paramount importance as it directly contributes to prolonging human lifespan and enhancing the quality of life. The discovery and clinical application of PD-1 (Programmed cell death 1), PD-L1 (Programmed cell death ligand 1), and CTLA-4 (Cytotoxic T lymphocyte antigen 4) and their inhibitors have introduced novel therapeutic approaches for combating malignant tumors [3,4,5,6,7].

PD-1/PD-L1 and CTLA-4 inhibitors fuction through distinct pathways. The PD-1/PD-L1 inhibitor operates by blocking the interaction between PD-1 located on T cell membranes and the overexpressed PD-L1 on cancer cell membranes, while CTLA-4 inhibitor works by blocking the binding of B7 on antigen-presenting cells to CTLA-4 in T cells [8, 9]. Monotherapy with PD-1 or PD-L1 inhibitors is limited for patients with solid malignancies, and new strategies are required [10]. Combining the CTLA-4/B7 axis blockade, as an auxiliary axis, with PD-1/PD-L1 axis blockade, has become a new direction of cancer immunotherapy [11, 12]. Several studies have demonstrated that the addition of a CTLA-4 inhibitor to PD-1/PD-L1 inhibitors benefits for patients with recurrent/metastatic solid malignancies [13,14,15,16,17,18]. In addition, results from randomized controlled trials (RCTs) have been published that compare the use of neoadjuvant PD-1/PD-L1 inhibitors alone with the combination of neoadjuvant PD-1/PD-L1 inhibitors and CTLA-4 inhibitors. However, these RCTs suffer from small sample sizes, scattered sites, and inconsistent results [19,20,21]. Furthermore, no related secondary studies have been published. Therefore, a systematic review and meta-analysis is needed to evaluate the effectiveness and safety of neoadjuvant therapy with CTLA-4 inhibitors added to PD-1/PD-L1 blockade for solid malignancies.

In accordance with the PICOS principle, we used overall response rate (ORR), main pathological response (MPR), pathological complete response (pCR), surgical resection, radical resection (R0 resection), overall survival (OS), progression-free survival (PFS) and recurrence-free survival (RFS) as the efficacy outcomes (O), and grade 3–4 adverse events (grade 3–4 AEs), all-cause mortality and completed treatment as the safety outcomes (O). We conducted a meta-analysis focusing on published RCTs (study design, S) comparing the efficacy and safety of the neoadjuvant combination therapy of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors (intervention, I) with neoadjuvant monotherapy of PD-1/PD-L1 inhibitors (comparison, C) for patients with solid malignancies (population, P) to provide theories for clinical applications or futural investigations.

Methods

Literature search strategy

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [22] and has been registered with the number CRD42023407275 on PROSPERO. Electronic databases such as PubMed, Embase, Web of Science, and the Cochrane Library were searched for records published from inception to March 17, 2023. Searches were conducted using using the following keywords with their subject terms and free words: “PD-1”, “PD-L1”, “CTLA-4”, “immunotherapy”, “neoadjuvant”, “cancer”, and “randomized controlled trial”. And the ClinicalTrial.gov registered website, European Society of Clinical Oncology, American Society of Clinical Oncology conference abstracts within the past 5 years, and references of all included articles were also manually searched (Table S1). Two authors (SH and GZ) performed the search independently and disagreements were resolved by consultation.

Inclusion and exclusion criteria

The inclusion criteria were as follows: (1) patients with solid malignancies diagnosed by histopathology; (2) without distant metastasis; (3) RCTs; (4) neoadjuvant PD-1 or/and PD-L1 inhibitor combined with CTLA-4 inhibitor were used for experimental groups; (5) neoadjuvant PD-1 or/and PD-L1 inhibitor was used for control groups; (6) at least one of the following outcomes was available: ORR, MPR, pCR, surgical resection, R0 resection, OS, PFS, RFS, grade 3–4 AEs, all-cause mortality and completed treatment; and (7) English publications.

The exclusion criteria were as follows: (1) reviews, systematic reviews, meta-analyses, letters, case reports, and public database analyses; (2) vitro and experimental animal studies; (3) unavailable outcomes; (4) less than five cases; and (5) duplicate studies. The most complete and latest articles were included, if duplicate reported cases were involved in different articles.

Data extraction

The process of data extraction was conducted independently by two authors (SH and GZ) according to the guide tables. The following information was extracted: authors, years, registration numbers, cancers, drugs administered in experimental and control groups, number of participants, and outcomes. The number of events and non-occurred events in experimental and control groups were extracted for ORR, MPR, pCR, surgical resection, R0 resection, grade 3–4 AEs, all-cause mortality, and completed treatment. Hazard ratios (HRs) and their 95% confidence interval (CI) were extracted for OS, PFS, and RFS. If HRs were not reported, we used Engauge Digitizer 4.1 software [23] and the method introduced by Jayne F Tierney [24] to extract the HR and 95% CI.

Data analysis

This meta-analysis was conducted using Stata17.0 MP and Review Manager 5.4. Heterogeneity among the included studies was assessed with the χ2 test and I2 test. Studies were considered heterogenous if P ≥ 0.1 and I2 ≤ 50%, and meta-analysis were performed using a fixed-effects model. On the contrary, a random-effect model was used when heterogeneity was observed. The Cochrane Risk of Bias Assessment Tool (ROB1) was used to assess the risk of biases in the included articles. Risk ratios (RRs) and their 95% CIs were calculated for ORR, MPR, pCR, surgical resection, R0 resection, grade 3–4 AEs, all-cause mortality, and completed treatment. HRs and their 95% CIs were calculated for OS, PFS, and RFS. Stability was assessed by sensitivity analysis, and further subgroup analyses were performed based on the use of PD-1 or PD-L1 inhibitors in control groups. Egger and begg test were used to evaluate publication biases. The test level was P = 0.05.

Results

Features and systematic review of the included studies

Detailed steps during the literature research are described in Fig. 1. A total of 2780 potential records were identified, and 891 duplicate records were removed. Finally, 10 studies [19,20,21, 25,26,27,28,29,30,31] were included in our study that met the criteria. Included articles were single-center RCTs published from November 2018 to January 2023. These articles consisted of seven full-text articles, two conference abstracts, and one clinical trial result report. Six studies used a combination of PD-1 inhibitors and CTLA-4 inhibitors, while four studies utilized PD-L1 inhibitors in combination with CTLA-4 inhibitors. Notably, none of the included studies used both PD-1 and PD-L1 inhibitors simultaneously. Four articles focused on head and neck squamous cell carcinoma, two on non-small cell lung cancer, one on pancreatic cancer, one on ovarian cancer, one on melanoma, and one on malignant pleural mesothelioma. A total of 273 participants were included in the study, with 137 participants in the experimental groups and 136 participants in the control groups. Table 1 summarized the specific features of the included articles. The assessment of bias is shown in Fig. S1.

Fig. 1
figure 1

Flowchart of the literature research process

Full size image
Table 1 Features of the included studies
Full size table

Meta-analysis

ORR, pCR and MPR

ORR: Six articles reported on ORR, involving 187 participants [19,20,21, 26, 28, 30]. The random-effect model was used because of significant heterogeneity among studies (I2 = 51.1%). Meta-analysis showed that there was no significant difference in ORR when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 inhibitor for patients with solid malignancies (RR 1.04, 95%CI 0.51–2.12, P = 0.91) (Fig. 2a). Subgroup analysis indicated that the addition of CTLA-4 inhibitors had no significant impact on ORR regardless of whether PD-1 or PD-L1 inhibitor were used (P > 0.05) (Fig. 2a).

Fig. 2
figure 2

Forest plot of overall response rate (ORR), main pathological response (MPR), and pathological complete response (pCR). a Forest plot of ORR. b Forest plot of MPR. c Forest plot of pCR

Full size image

MPR: Seven articles reported on MPR, involving 232 participants [19,20,21, 26, 28, 29, 31]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that there is no significant difference in MPR when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 inhibitor for patients with solid malignancies (RR 1.14, 95%CI 0.71–1.84, P = 0.58) (Fig. 2b). Subgroup analysis showed that the addition of CTLA-4 inhibitors had no significant impact on MPR regardless of whether PD-1 or PD-L1 inhibitor were used (P > 0.05) (Fig. 2b).

pCR: Four articles reported on pCR, involving 119 participants [20, 21, 26, 28]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that the additional CTLA-4 inhibitors had no significant impact on pCR (RR 1.97, 95%CI 0.92–4.23, P = 0.08) (Fig. 2c).

Surgical resection

Four articles reported on surgical resection, involving 158 participants [20, 21, 25, 29]. The fixed-effect model was used because of homogeneity among studies (I2 = 13.0%). Meta-analysis showed that there is no significant difference in surgery when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 inhibitor for patients with solid malignancies (RR 0.98, 95%CI 0.82–1.17, P = 0.83) (Fig. 3a).

Fig. 3
figure 3

Forest plot of surgical resection and residual 0 resection (R0). a Forest plot of surgical resection. b Forest plot of R0 resection

Full size image

Two of those four articles further reported on R0 resection. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that the addition of CTLA-4 inhibitors had no significant impact on R0 resection (RR 0.89, 95%CI 0.69–1.14, P = 0.36) (Fig. 3b).

Survivals

OS: OS was reported in three studies, involving 96 participants [19, 21, 26]. The fixed-effect model was used because of homogeneity among studies (I2 = 12.6%). Meta-analysis showed that the addition of CTLA-4 inhibitors had no significant impact on prolonging OS of patients (HR 0.78, 95% CI 0.18–3.29, P = 0.74) (Fig. 4a).

Fig. 4
figure 4

Forest plot of overall survival (OS), progression-free survival (PFS), and recurrence-free survival (RFS). a Forest plot of OS. b Forest plot of PFS. c Forest plot of RFS

Full size image

PFS: Three studies reported on PFS, involving 79 participants [19,20,21]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that there is no significant difference in PFS when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 inhibitor for patients with solid malignancies (HR 1.08, 95%CI 0.47–2.49, P = 0.87) (Fig. 4b).

RFS: Two studies reported on RFS, involving 67 participants [21, 26]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that there is no significant difference in RFS when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 inhibitor for patients with solid malignancies (HR 1.05, 95%CI 0.31–3.54, P = 0.94) (Fig. 4c).

Grade 3–4 AEs

Grade 3–4 AEs were reported in seven studies, involving 242 participants [19,20,21, 26, 28, 29, 31]. The fixed-effect model was used because of homogeneity among studies (I2 = 16.1%). Meta-analysis showed that there was no significant difference in grade 3–4 AEs when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 blockade for patients with solid malignancies (RR 1.44, 95%CI 0.95–2.19, P = 0.08) (Fig. 5a). Further subgroup analysis indicated that addition of CTLA-4 inhibitor significantly increased grade 3–4 AEs of patients when PD-1 inhibitor was used (P < 0.05), but had no significant impact when PD-L1 inhibitor was used (P > 0.05) (Fig. 5a).

Fig. 5
figure 5

Forest plot of safety. a Forest plot of grade 3–4 adverse events. b Forest plot of all-cause mortality. c Forest plot of completed treatment

Full size image

All-cause mortality

All-cause mortality was reported in three studies, involving 101 participants [20, 25, 27]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that the addition of CTLA-4 inhibitors had no significant impact on all-cause mortality (RR 1.49, 95%CI 0.44–5.10, P = 0.52) (Fig. 5b).

Completed treatment

Three studies composed of 143 participants were included [26, 27, 29]. The fixed-effect model was used because of homogeneity among studies (I2 = 0%). Meta-analysis showed that there was no significant difference in completed treatment when CTLA-4 inhibitors were added to neoadjuvant PD-1/PD-L1 blockade for patients with solid malignancies (RR 0.96, 95%CI 0.86–1.08, P = 0.51) (Fig. 5c).

Sensitivity analysis and publication bias

A sensitivity analysis conducted on the included studies, which showed that the results of ORR, MPR, pCR, surgical resection, R0 resection, OS, PFS, RFS, all-cause mortality, and completed treatment remained stable even when each study was removed. However, upon excluding the study by Renata Ferrarotto et al., a change in the result for grade 3–4 AEs was observed, indicating instability in the findings related to grade 3–4 AEs (Fig. S2 and Fig. S3). Furthermore, the egger test and begg test showed no significant publication bias in the analyzed studies(P > 0.05) (Table S2).

Discussion

Antitumor immunity is positively correlated with cellular immunity, primarily mediated by T cells [32, 33]. Activation of cytotoxic T cells relies not only on positive costimulatory signals from the T cell receptor (TCR) binding to tumor antigens, but also on negative coinhibitory signals, such as the PD-1/PD-L1 axis and CTLA-4/B7 axis [34, 35]. Coinhibitory signals become hyperactivated because of overexpressed CTLA-4 in cytotoxic T cells or Treg cells induced by tumors, and overexpressed PD-L1 on tumor cells. Consequently, the activation of T cells is blocked [36, 37]. PD-1/PD-L1 and CTLA-4 inhibitors block the hyperactivated PD-1/PD-L1 axis and CTLA-4/B7 axis respectively, and make effects [11]. Some researchers believe that the overexpressed PD-L1 on cancer cells can suppress the expression of CTLA-4 [38], and the retention of CTLA-4 may weaken the immune activation effect of PD-L1 blockade. Currently, there is controversy regarding whether to block the PD-1/PD-L1 axis and the CTLA-4 simultaneously during neoadjuvant therapy for solid malignancies. Some RCTs have indicated that the additional CTLA-4 blockade is effective and well-tolerated, while others demonstrated that the addition of CTLA-4 inhibitor is inefficient with more adverse events [19,20,21]. This study included 10 RCTs and shows that adding CTLA-4 inhibitors to PD-1/PD-L1 inhibitors cannot significantly increase ORR, MPR, pCR, surgical resection, prolong the survival time of patients, or improve the safety as neoadjuvant therapy for solid malignancies. Our study supports that the CTLA-4/B7 axis can remain unblocked when treating patients with solid malignancies using neoadjuvant PD-1/PD-L1 inhibitors.

Publications have shown that chemotherapy or radiotherapy can positively affect immune checkpoint inhibitors by inducing inflammatory responses in tumor environments [39,40,41,42]. When treating the recurrent/metastatic solid malignancies, the combination of PD-1 or PD-L1 inhibitors and CTLA-4 inhibitors is often used as curative or adjuvant therapy. These agents are often administered prior to or concurrently with traditional chemotherapy or radiotherapy, resulting in favorable clinical outcomes [43, 44]. However, when considering neoadjuvant therapy, only one article was in our study where induced chemotherapy was used before combing PD-1 with CTLA-4 inhibition. Therefore, we speculate that the lack of radiation or chemotherapy induction could be a potential reason for the limited improvement in the efficacy of the additional CTLA-4 inhibition in current studies. Therefore, a combination of traditional radiotherapy or chemotherapy holds promise for enhancing both efficacy and safety. Moreover, individualized combination strategies can be adopted based on differing molecular mechanisms and genomic profiles [45, 46].

In this study, we performed sensitivity analyses and found that the meta-analyses of each efficacy outcome, all-cause mortality, and treatment completion rate remained stable, but the results of grade ≥ 3 AEs were unstable. Additionally, we found that when using PD-1 inhibitors combined with CTLA-4 inhibitors for neoadjuvant therapy for patients with solid maligancies, the grade ≥ 3 AEs significantly increased. This study indicates that the need for further research to investigate whether the combination of neoadjuvant PD-1/PD-L1 inhibitors and CTLA-4 inhibitors leads to an increased rate of AEs.

According to PD-1 or PD-L1 inhibitors, we performed further subgroup analyses. The analyses revealed that the forest plot of ORR and MPR in the PD-1 inhibitor subgroup is more favorable to the experimental group than the PD-L1 inhibitor subgroup, but with no statistical difference. Additionally, the combination of PD-1 and CTLA-4 inhibitors significantly increased the grade 3–4 AEs, whereas PD-1 and CTLA-4 inhibitors did not. When CTLA-4 inhibitors were introduced, this difference between PD-1 and PD-L1 inhibitors may be attributed to the interaction of the PD-1/PD-L1 axis and CTLA-4/B7 axis. Binding of PD-L2 to PD-1 can significantly inhibit CD28 binding to B7 and promote the binding of CTLA-4 to B7 [47]. PD-L1 inhibitors promote the binding of CTLA-4 to B7 and weaken the efficacy of CTLA-4 inhibitors by blocking PD-L1 and retaining PD-L2. On the contrary, PD-L1 and PD-L2 are blocked by PD-1 inhibitors, allowing the efficacy of CTLA-4 inhibitors to remain umimpaired. In addition, CTLA-4 inhibitors can also participate in antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [48]. Ipilimumab (PD-1 inhibitor) is an antibody of IgG1 that facilitates participation in ADCC or CDC, while tremelimumab (PD-L1 inhibitor) is an antibody of IgG2 which does not engage in these two pathways [49, 50]. This suggests that, compared with the PD-L1 inhibitor, PD-1 inhibitors plus CTLA-4 inhibitors may offer greater efficacy but may slao result in more adverse events.

This study is the first meta-analysis to summarize the efficacy and safety of PD-1 or PD-L1 inhibitors combined with CTLA-4 inhibitors versus mono PD-1 or PD-L1 inhibitors as neoadjuvant therapy for patients with solid malignancies. And it demonstrates that combining PD-1 or PD-L1 inhibitors with CTLA-4 inhibitors is not beneficial. And there are no significant publication biases. However, our study possesses certain limitations. Firstly, further studies are needed in the future because of the small samples and single-center included studies in our study. Secondly, we cannot conduct more detailed subgroup analyses based on different carcinomas due to limited data. Finally, it is important to acknowledge that some HRs of survival were extracted from survival curves, which may introduce potential systematic errors.

Conclusion

Our study indicates that, as neoadjuvant therapy for solid malignancies, current evidence does not support adding CTLA-4 inhibitors to neoadjuvant PD-1/PD-L1 inhibitors. Moreover, PD-1 inhibitors may be more effective, but potentially increased grade 3–4 adverse events should be concerned.

Availability of data and materials

All data generated or analyzed during this study are included in the article or supplementary materials.

Abbreviations

PD-1:

Programmed cell death 1

PD-L1:

Programmed cell death ligand 1

CTLA-4:

Cytotoxic T Lymphocyte antigen 4

RCTs:

Randomized controlled trials

ORR:

Overall response rate

MPR:

Main pathological response

pCR:

Pathological complete response

R0 resection:

Radical resection

OS:

Overall survival

PFS:

Progression-free survival

RFS:

Recurrence-free survival

AEs:

Adverse events

PICOS:

Population, intervention, comparison, outcomes and study design

PRISMA:

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

HR:

Hazard ratio

CI:

Confidence interval

RR:

Risk ratios

ROB1:

Cochrane Collaboration's tool for assessing risk of bias in randomized trials

TCR:

T cell receptor

ADCC:

Antibody-dependent cellular cytotoxicity

CDC:

Complement-dependent cytotoxicity

References

  1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer. 2021;127(16):3029–30.

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  3. Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol. 2022;19(1):37–50.

    Article  CAS  PubMed  Google Scholar 

  4. Krummel M. Nobel notes value of basic research for new drugs. Nature. 2018;563(7730):184.

    Article  CAS  PubMed  Google Scholar 

  5. Ledford H, Else H, Warren M. Cancer immunologists scoop medicine Nobel prize. Nature. 2018;562(7725):20–1.

    Article  CAS  PubMed  Google Scholar 

  6. Barone B, Calogero A, Scafuri L, Ferro M, Lucarelli G, Di Zazzo E, et al. Immune checkpoint inhibitors as a neoadjuvant/adjuvant treatment of muscle-invasive bladder cancer: a systematic review. Cancers. 2022;14(10):2545r.

    Article  Google Scholar 

  7. Iacovino ML, Miceli CC, De Felice M, Barone B, Pompella L, Chiancone F, et al. Novel therapeutic opportunities in neoadjuvant setting in urothelial cancers: a new horizon opened by molecular classification and immune checkpoint inhibitors. Int J Mol Sci. 2022;23(3):1133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sugiura D, Maruhashi T, Okazaki IM, Shimizu K, Maeda TK, Takemoto T, et al. Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science. 2019;364(6440):558–66.

    Article  CAS  PubMed  Google Scholar 

  9. Sun C, Mezzadra R, Schumacher TN. Regulation and Function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Maghrouni A, Givari M, Jalili-Nik M, Mollazadeh H, Bibak B, Sadeghi MM, et al. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: preclinical evidence and clinical interventions. Int Immunopharmacol. 2021;93:107403.

    Article  CAS  PubMed  Google Scholar 

  11. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.

    Article  PubMed  Google Scholar 

  12. Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol. 2022:[JCO2200221 p.]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35867951.

  13. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol. 2020;31(7):942–50.

    Article  CAS  PubMed  Google Scholar 

  15. Paz-Ares LG, Ramalingam SS, Ciuleanu TE, Lee JS, Urban L, Caro RB, et al. First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 checkmate 227 part 1 trial. J Thorac Oncol. 2022;17(2):289–308.

    Article  CAS  PubMed  Google Scholar 

  16. Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239–53.

    Article  CAS  PubMed  Google Scholar 

  17. D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018;19(3):416–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Klein O, Kee D, Gao B, Markman B, da Gama DJ, Quigley L, et al. Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209–538 clinical trial. J Immunother Cancer. 2021;9(11):e003156.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMA Oncol. 2020;6(10):1563–70.

    Article  PubMed  Google Scholar 

  20. Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey J-N, Lee SS, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(3):208–18.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657–65.

    Article  PubMed  Google Scholar 

  23. Markmitch. Engauge Digitizer 4.1 https://engauge-digitizer.updatestar.com/: Updatestar; 2008 [cited 2022 6.8]. Available from: https://engauge-digitizer.updatestar.com/.

  24. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Sepesi B, Zhou N, William WN Jr, Lin HY, Leung CH, Weissferdt A, et al. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022;164(5):1327–37.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021;27(3):504–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, et al. Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity www.clinicaltrials.gov: www.clinicaltrials.gov; 2022 [Available from: https://www.clinicaltrials.gov/ct2/show/NCT02919683?term=NCT02919683&draw=2&rank=1.

  28. Ferrarotto R, Bell D, Rubin ML, Hutcheson KA, Johnson JM, Goepfert RP, et al. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8(+) Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results. Clin Cancer Res. 2020;26(13):3211–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Leary A, Rouge TDLM, Lortholary A, Asselain B, Alexandre J, Floquet A, et al. Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study. Ann Oncol. 2021;32(suppl_5):S725–72.

    Google Scholar 

  30. Hong MH, Kim CG, Kim DH, Lim SM, Ahn BC, Kim SH, et al. 860MO Preoperative durvalumab (D) with or without tremelimumab (T) for resectable head and neck squamous cell carcinoma (HNSCC). Ann Oncol. 2021;32:S787.

  31. Lee HS, Jang HJ, Ramineni M, Wang DY, Ramos D, Choi JM, et al. A phase II window of opportunity study of neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 blockade for patients with malignant pleural mesothelioma. Clin Cancer Res. 2023;29(3):548–59.

    Article  CAS  PubMed  Google Scholar 

  32. Demaria O, Cornen S, Daeron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.

    Article  CAS  PubMed  Google Scholar 

  33. Kelliher MA, Roderick JE. NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. Front Immunol. 2018;9:1718.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, et al. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol. 2022;15(1):111.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Gaikwad S, Agrawal MY, Kaushik I, Ramachandran S, Srivastava SK. Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy. Semin Cancer Biol. 2022;86(Pt 3):137–50.

    Article  CAS  PubMed  Google Scholar 

  36. Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40(1):184.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, et al. Design and efficacy of a monovalent bispecific PD-1/CTLA4 antibody that enhances CTLA4 blockade on PD-1(+) activated T cells. Cancer Discov. 2021;11(5):1100–17.

    Article  CAS  PubMed  Google Scholar 

  38. Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, et al. Programmed cell death-1 and its ligands: Current knowledge and possibilities in immunotherapy. Clinics (Sao Paulo, Brazil). 2023;78:100177.

    Article  PubMed  Google Scholar 

  39. Voorwerk L, Slagter M, Horlings HM, Sikorska K, van de Vijver KK, de Maaker M, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. Nat Med. 2019;25(6):920–8.

    Article  CAS  PubMed  Google Scholar 

  40. Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Nie J, Wang C, Liu Y, Yang Q, Mei Q, Dong L, et al. Addition of low-dose decitabine to Anti-PD-1 antibody camrelizumab in relapsed/refractory classical hodgkin lymphoma. J Clin Oncol. 2019;37(17):1479–89.

    Article  CAS  PubMed  Google Scholar 

  42. Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, Kao KZ, Lako A, Tsuji J, et al. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2022;23(2):279–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Huo G, Liu W, Zhang S, Chen P. Efficacy of PD-1/PD-L1 plus CTLA-4 inhibitors in solid tumors based on clinical characteristics: a meta-analysis. Immunotherapy. 2023;15(3):189–207.

    Article  CAS  PubMed  Google Scholar 

  44. Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38(1):255.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Cuccu I, D’Oria O, Sgamba L, De Angelis E, GoliaD’Augè T, Turetta C, et al. Role of genomic and molecular biology in the modulation of the treatment of endometrial cancer: narrative review and perspectives. Healthcare (Basel, Switzerland). 2023;11(4):571.

    PubMed  PubMed Central  Google Scholar 

  46. GoliaD’Augè T, Cuccu I, Santangelo G, Muzii L, Giannini A, Bogani G, et al. Novel insights into molecular mechanisms of endometrial diseases. Biomolecules. 2023;13(3):499.

    Article  Google Scholar 

  47. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–8.

    Article  CAS  PubMed  Google Scholar 

  48. Ingram JR, Blomberg OS, Rashidian M, Ali L, Garforth S, Fedorov E, et al. Anti-CTLA-4 therapy requires an Fc domain for efficacy. Proc Natl Acad Sci U S A. 2018;115(15):3912–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Furness AJS, Vargas FA, Peggs KS, Quezada SA. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol. 2014;35(7):290–8.

    Article  CAS  PubMed  Google Scholar 

  50. Wei SC, Anang NAS, Sharma R, Andrews MC, Reuben A, Levine JH, et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc Natl Acad Sci U S A. 2019;116(45):22699–709.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by Natural Science Foundation of Chongqing, China (cstc2018jcyjAX0208) and Chongqing Talents · Innovation Leading Talents Project (CQYC20200303128).

Author information

Author notes

  1. Gang Zheng and Kai Yang contributed equally to this work.

Authors and Affiliations

  1. Department of Stomatology, Shapingba Hospital affiliated to Chongqing University, No.44, Xiaolongkan New Street, Chongqing, Shapingba District, 400030, China

    Shuang Huang

  2. Anorectal Department, Chongqing Traditional Chinese Medicine Hospital, 6 Panxi 7 Road, Jiangbei District, Chongqing, 400021, China

    Gang Zheng

  3. Department of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Chongqing Medical University, No.1, Youyi Road, Yuzhong District, Chongqing, 400016, China

    Kai Yang

Authors
  1. Shuang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gang Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kai Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

SH, GZ and KY designed the study. SH and GZ performed the literature search, data extraction and quality assessment. SH, GZ and KY performed statistical analysis and interpreted. SH drafted the manuscript. GZ and KY revised the manuscript. All the authors read and approved the final manuscript, including the authorship list.

Corresponding authors

Correspondence to Gang Zheng or Kai Yang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huang, S., Zheng, G. & Yang, K. Neoadjuvant PD-1/PD-L1 combined with CTLA-4 inhibitors for solid malignancies: a systematic review and meta-analysis. World J Surg Onc 21, 349 (2023). https://doi.org/10.1186/s12957-023-03212-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12957-023-03212-5

Keywords

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us